Groupama Asset Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.47M | Buy |
175,531
+31,043
| +21% | +$438K | 0.04% | 162 |
|
|
2025
Q1 | $2.14M | Buy |
144,488
+34,281
| +31% | +$507K | 0.04% | 176 |
|
|
2024
Q4 | $2.23M | Buy |
110,207
+32,162
| +41% | +$651K | 0.05% | 185 |
|
|
2024
Q3 | $1.83M | Buy |
78,045
+5,657
| +8% | +$132K | 0.05% | 187 |
|
|
2024
Q2 | $1.68M | Buy |
72,388
+28,561
| +65% | +$663K | 0.02% | 234 |
|
|
2024
Q1 | $899K | Buy |
43,827
+8,814
| +25% | +$181K | 0.02% | 325 |
|
|
2023
Q4 | $752K | Buy |
+35,013
| New | +$752K | 0.02% | 310 |
|